Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VITX - new IPO with room to grow -- Ignore unavailable to you. Want to Upgrade?

To: BomboochaBoy who wrote (13)	9/25/1998 8:12:00 AM
From: Ariella	Read Replies (1) \| Respond to of 37

Dear Lurker, you've got to do better homework! "Lone customer" doesn't begin to describe the relationship between American Red Cross and VITX. ARC has, in fact, an "exclusive" contract to use the VITX blood wash process and there was nearly an antitrust suit by non-ARC US blood banks who feared they wouldn't get to use the process and their clients would no longer want their blood supplies. (The CFO has told me on the phone the suit will not go forward because ARC will make the blood available to the other banks.) ARC has 45% of the total US blood market, not insignificant for a "lone customer"! Also, your thought that sales are "down" is wrong. The company is ramping up. What has happened is that the increase in volumes is coming on a bit slower than originally forecast. This does not translate into "down." The pipeline was filled just last quarter, so we won't actually know how real growth rates are going for a couple of quarters. -Ariella